Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Banner Sun Health Research Institute, Sun City, Arizona, USA.
Ann Clin Transl Neurol. 2023 May;10(5):696-705. doi: 10.1002/acn3.51753. Epub 2023 Mar 27.
Detection of α-synuclein aggregates by seed amplification is a promising Parkinson disease biomarker assay. Understanding intraindividual relationships of α-synuclein measures could inform optimal biomarker development. The objectives were to test accuracy of α-synuclein seed amplification assay in central (cerebrospinal fluid) and peripheral (submandibular gland) sources, compare to total α-synuclein measures, and investigate within-subject relationships.
The Systemic Synuclein Sampling Study aimed to characterize α-synuclein in multiple tissues and biofluids within Parkinson disease subjects (n = 59) and compared to healthy controls (n = 21). Motor and non-motor measures and dopamine transporter scans were obtained. Four measures of α-synuclein were compared: seed amplification assay in cerebrospinal fluid and formalin-fixed paraffin-embedded submandibular gland, total α-synuclein quantified in biofluids using enzyme-linked immunoassay, and aggregated α-synuclein in submandibular gland detected by immunohistochemistry. Accuracy of seed amplification assay for Parkinson disease diagnosis was examined and within-subject α-synuclein measures were compared.
Sensitivity and specificity of α-synuclein seed amplification assay for Parkinson disease diagnosis was 92.6% and 90.5% in cerebrospinal fluid, and 73.2% and 78.6% in submandibular gland, respectively. 25/38 (65.8%) Parkinson disease participants were positive for both cerebrospinal fluid and submandibular gland seed amplification assay. Comparing accuracy for Parkinson disease diagnosis of different α-synuclein measures, cerebrospinal fluid seed amplification assay was the highest (Youden Index = 83.1%). 98.3% of all Parkinson disease cases had ≥1 measure of α-synuclein positive.
α-synuclein seed amplification assay (cerebrospinal fluid>submandibular gland) had higher sensitivity and specificity compared to total α-synuclein measures, and within-subject relationships of central and peripheral α-synuclein measures emerged.
通过种子扩增检测α-突触核蛋白聚集物是一种很有前途的帕金森病生物标志物检测方法。了解α-突触核蛋白测量值的个体内关系可以为最佳生物标志物的发展提供信息。本研究的目的是测试α-突触核蛋白种子扩增检测在中枢(脑脊液)和外周(颌下腺)来源中的准确性,与总α-突触核蛋白测量值进行比较,并研究个体内的关系。
系统性突触核蛋白采样研究旨在对帕金森病患者(n=59)和健康对照者(n=21)的多个组织和生物液中的α-突触核蛋白进行特征描述。获得了运动和非运动测量值以及多巴胺转运蛋白扫描。比较了四种α-突触核蛋白的测量值:脑脊液中的种子扩增检测、福尔马林固定石蜡包埋的颌下腺中的总α-突触核蛋白、使用酶联免疫吸附测定法在生物液中定量的总α-突触核蛋白,以及通过免疫组化检测到的颌下腺中的聚集α-突触核蛋白。检查了种子扩增检测对帕金森病诊断的准确性,并比较了个体内的α-突触核蛋白测量值。
α-突触核蛋白种子扩增检测对帕金森病诊断的敏感性和特异性在脑脊液中分别为 92.6%和 90.5%,在颌下腺中分别为 73.2%和 78.6%。38 名帕金森病患者中有 25 名(65.8%)脑脊液和颌下腺种子扩增检测均为阳性。比较不同α-突触核蛋白测量值对帕金森病诊断的准确性,脑脊液种子扩增检测的准确性最高(约登指数为 83.1%)。所有帕金森病病例中有 98.3%的病例至少有一种α-突触核蛋白检测结果为阳性。
α-突触核蛋白种子扩增检测(脑脊液>颌下腺)的敏感性和特异性均高于总α-突触核蛋白测量值,并且出现了中枢和外周α-突触核蛋白测量值的个体内关系。